Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CMIn vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.J Exp Med 210(5) 951-68 5/6/2013
Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71(5) 1183-90 5/1/2013
Wang C, Pécot T, Zynger DL, Machiraju R, Shapiro CL, Huang KIdentifying survival associated morphological features of triple negative breast cancer using multiple datasets.J Am Med Inform Assoc in press 4/25/2013
Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das HHuman Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules, and microenvironment in tumors.Int J Cancer in press 4/18/2013
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CLEffect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA 309(13) 1359-67 4/3/2013
Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CLIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.Ann Oncol in press 3/4/2013
Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner KIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.PLoS One 8(2) e55910 1/1/2013
Lustberg MB, Reinbolt RE, Shapiro CLBone health in adult cancer survivorship.J Clin Oncol 30(30) 3665-74 10/20/2012
Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder SHedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.Cancer Res 72(19) 5048-59 10/1/2012
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MVMicrocirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.Magn Reson Imaging 30(8) 1059-67 10/1/2012
Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer 20(9) 1991-7 9/1/2012
Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL, Huebner KStem cell-related markers in primary breast cancers and associated metastatic lesions.Mod Pathol 25(7) 949-55 7/1/2012
Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CLPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.Cancer Chemother Pharmacol 70(1) 49-56 7/1/2012
Chuang HC, Kapuriya N, Kulp SK, Chen C, Shapiro CLDifferential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.Breast Cancer Res Treat 134(2) 649-59 7/1/2012
Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CLDifferential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.Breast Cancer Res Treat 134(2) 649-59 7/1/2012
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JAPhase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.Breast Cancer Res Treat 132(3) 1063-72 4/1/2012
Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CLPhase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.Clin Breast Cancer 12(2) 151-6 4/1/2012
Fagundes CP, Lindgren ME, Shapiro CL, Kiecolt-Glaser JKChild maltreatment and breast cancer survivors: social support makes a difference for quality of life, fatigue and cancer stress.Eur J Cancer 48(5) 728-36 3/1/2012
Ligibel JA, Meyerhardt J, Pierce JP, Najita J, Shockro L, Campbell N, Newman VA, Barbier L, Hacker E, Wood M, Marshall J, Paskett E, Shapiro CImpact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting.Breast Cancer Res Treat 132(1) 205-13 2/1/2012
Peng Z, Shen R, Li YW, Teng KY, Shapiro CL, Lin HJEpigenetic repression of RARRES1 is mediated by methylation of a proximal promoter and a loss of CTCF binding.PLoS One 7(5) e36891 1/1/2012
Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST, Majumder SAnti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.J Biol Chem 286(49) 42292-302 12/9/2011
Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CSTargeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.J Biol Chem 286(45) 39247-58 11/11/2011
Gordon AM, Hurwitz S, Shapiro CL, Leboff MSPremature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.Menopause 18(11) 1244-8 11/1/2011
Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J, Chen J, Kamal J, Shapiro CL, Huebner KAberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.Breast Cancer Res Treat 129(2) 421-32 9/1/2011
Fagundes CP, Murray DM, Hwang BS, Gouin JP, Thayer JF, Sollers JJ 3rd, Shapiro CL, Malarkey WB, Kiecolt-Glaser JKSympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors.Psychoneuroendocrinology 36(8) 1137-47 9/1/2011
Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CLPhase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.Clin Breast Cancer 11(4) 221-7 8/1/2011
Kais Z, Barsky SH, Mathsyaraja H, Zha A, Ransburgh DJ, He G, Pilarski R, Shapiro CL, Huang K, Parvin JDKIAA0101 interacts with BRCA1 and regulates centrosome number.Mol Cancer Res 9(8) 1091-9 8/1/2011